NxStage Medical announces CE Mark approval for new high flow capabilities NxStage Medical announced CE Mark approval for new high flow capabilities with the NxStage System One. With this approval, the company expects to bring this advancement to customers in countries that recognize the CE Mark approval process later this year.
News For NXTM From The Last 14 Days
Check below for free stories on NXTM the last two weeks.
NxStage Medical downgraded to Underperform from Market Perform at Wells Fargo Wells Fargo downgraded NxStage Medical to Underperform on concern the company's plans to 10-15 dialysis centers in the U.S. by the end of 2014 will not significantly increase the number of home hemodialysis patients and may put in-center revenue at risk. Wells lowered its price target range for shares to $10-$12 from $11-$14.